ArticleJournal of the American Society of Nephrology : JASN2011
Cystatin C identifies chronic kidney disease patients at higher risk for complications.
Article in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it, 228 citations in OpenAlex.
- Cystatin C versus creatinine in determining risk based on kidney function.The New England journal of medicine · 2013Pooled it
- Is there a renoprotective value to leukodepletion during heart valve surgery? A randomized controlled trial (ROLO).Journal of cardiothoracic surgery · 2021Trial
- The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020Trial
- Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans.BMC nephrology · 2017Trial
- Identification of incident CKD stage 3 in research studies.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014Trial
- Trial
- Effect of prolonged standardized bed rest on cystatin C and other markers of cardiovascular risk.BMC physiology · 2011Trial
- Glomerular filtration rate estimation in nephrotic patients: creatinine and/or cystatin-C-based equations, or none of them?Clinical kidney journal · 2026Article
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts.Age and ageing · 2026Article
- Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review.Current atherosclerosis reports · 2025Article
- Association of cystatin C with 20-year mortality risk in the general US population: a cohort study.Renal failure · 2025Article
- Difference between cystatin C- and creatinine-based estimated glomerular filtration rate and incident hypertension and the mediating role of Triglyceride Glucose Index.Renal failure · 2025Article
- Incremental Prognostic Value of Cystatin C-Based Estimated Glomerular Filtration Rate in Patients With Acute Coronary Syndrome.Reviews in cardiovascular medicine · 2025Article
- Associations of cystatin C with incident chronic kidney disease and all-cause mortality in patients with normal glucose tolerance and prediabetes.Scientific reports · 2025Article
- Emerging Biomarkers and Advanced Diagnostics in Chronic Kidney Disease: Early Detection Through Multi-Omics and AI.Diagnostics (Basel, Switzerland) · 2025Review
- Integrating aging biomarkers and immune function to predict kidney health: insights from the future of families and child wellbeing study.GeroScience · 2025Article
- Cystatin-c / total cholesterol ratio as a predictor of probable sarcopenia in geriatric population from 12 European countries.Aging clinical and experimental research · 2025Article
- Exploring the association of metabolic factors and chronic musculoskeletal pain over a period of 10 years - the Doetinchem Cohort Study.Clinical rheumatology · 2025Article
- A Comparison of Creatinine, Cystatin C, and Creatinine-Cystatin C Based Equations in HIV/AIDS Patients: A Cross-Sectional Study.Health science reports · 2024Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Although cystatin C is a stronger predictor of clinical outcomes associated with CKD than creatinine, the clinical role for cystatin C is unclear. We included 11,909 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS) and assessed risks for death, cardiovascular events, heart failure, and ESRD among persons categorized into mutually exclusive groups on the basis of the biomarkers that supported a diagnosis of CKD (eGFR <60 ml/min per 1.73 m(2)): creatinine only, cystatin C only, both, or neither. We used CKD-EPI equations to estimate GFR from these biomarkers. In MESA, 9% had CKD by the creatinine-based equation only, 2% had CKD by the cystatin C-based equation only, and 4% had CKD by both equations; in CHS, these percentages were 12, 4, and 13%, respectively. Compared with those without CKD, the adjusted hazard ratios (HR) for mortality in MESA were: 0.80 (95% CI 0.50 to 1.26) for CKD by creatinine only; 3.23 (95% CI 1.84 to 5.67) for CKD by cystatin C only; and 1.93 (95% CI 1.27 to 2.92) for CKD by both; in CHS, the adjusted HR were 1.09 (95% CI 0.98 to 1.21), 1.78 (95% CI 1.53 to 2.08), and 1.74 (95% CI 1.58 to 1.93), respectively. The pattern was similar for cardiovascular disease (CVD), heart failure, and kidney failure outcomes. In conclusion, among adults diagnosed with CKD using the creatinine-based CKD-EPI equation, the adverse prognosis is limited to the subset who also have CKD according to the cystatin C-based equation. Cystatin C may have a role in identifying persons with CKD who have the highest risk for complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.